Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 86 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Lesion Biopsies Clear all

Conditions: Glioma, Glioblastoma, Metastatic Malignant Neoplasm in the Brain
Interventions: Microdialysis, Magnetic Resonance Imaging, Computed Tomography; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Gastrointestinal Carcinoma, Pancreatic Carcinoma, Lung Cancer, Esophageal Carcinoma
Interventions: Narrow Band Imaging (NBI); Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: GI Lesions
Interventions: Pro Core Needle, medtronic Sharkcore Needle; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Actinic Keratosis, Squamous Cell Carcinoma
Interventions: Superficial shave biopsy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases
Interventions: MIMIG System, Indocyanine Green (ICG); Device · Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioma
Interventions: Magnetic Resonance Elastography, Magnetic Resonance Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Nanomechanical Phenotype Test; Diagnostic Test
Lead sponsor: ARTIDIS AG; Industry
Eligibility: 18 Years and older
Enrollment: 2,706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Seattle, Washington

Conditions: Cervical Cancer, Cervical Intraepithelial Neoplasias, Digital Colposcopy, Precancerous Cervical Lesions
Interventions: Diagnostic imaging aid for one-visit management of cervical lesions; Device
Lead sponsor: Brookdale University Hospital Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Pancreas, Mass Lesion
Interventions: Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe), Saline; Combination Product · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Prostate Cancer, Prostate Cancer
Interventions: 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire; Drug · Procedure · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cerebrovascular Disorders, Intracranial Neoplasms
Interventions: Fluorescein Sodium; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Melanoma
Interventions: Dermatology patients; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Anal High Grade Squamous Intraepithelial Lesion
Interventions: mHRME (Mobile High resolution microendoscope), Proflavine Hemisulfate, High resolution anoscopy; Diagnostic Test · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: New York, New York • Houston, Texas

Conditions: Breast Cancer, Melanoma
Interventions: Multispectral Optoacoustic Tomography Imaging; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Montvale, New Jersey • Commack, New York • New York, New York

Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone; Procedure · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lung Diseases
Interventions: Flush; Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pancreatic Cancer, Lymphadenopathy, Cholangiocarcinoma
Interventions: 22G SharkCore™ needle, 22G BNX EUS-FNA Needle; Device
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Histiocytic Disorders
Interventions: F-choline PET Scan, FDG-PET, biopsy; Radiation · Device · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Triple Negative Breast Cancer
Interventions: Needle core biopsies, Needle core biopsies of metastatic lesion; Procedure
Lead sponsor: Jewish General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carcinoma, Intraductal, Noninfiltrating, DCIS, Ductal Carcinoma In Situ
Interventions: Chloroquine Standard Dose (500mg/week), Chloroquine Low Dose (250mg/week), Breast Biopsy; Drug · Procedure
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 4
States / cities: Fairfax, Virginia • Falls Church, Virginia

Conditions: Breast Cancer, Breast Cancer Surgery
Interventions: Positron Emission Mammography (PEM); Device
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone; Device · Combination Product
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more

Conditions: Prostate Cancer
Interventions: [18F]-DCFPyl Ligand; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Osteosarcoma
Interventions: standard of care biopsy; Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions

Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive

Endoscopic Ultrasound (EUS) Fine Needle Biopsy (FNB) Submucosal Nodule

Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Diagnostic Imaging Aid for Management of Cervical Lesions

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions

Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques

The Effectiveness of High Resolution Microendoscopy for People Living With HIV

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Cold Saline Irrigation Before Endobronchial Biopsy

Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle

Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

An Organoid-based Functional Precision Medicine Trial in Osteosarcoma